LEPU BIO(02157),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

02157 LEPU BIO

Closed 07-17 16:08:11

4.470

-0.360

-7.45%

High4.840	Low4.350	Vol13.87M
Open4.840	D1 Closing4.830	Amplitude10.14%
Mkt Cap8.06B	Tradable Cap8.06B	Total Shares1.80B
T/O62.27M	T/O Rate0.77%	Tradable Shares1.80B
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"02157","market":"HK","secType":"STK","nameCN":"LEPU BIO","latestPrice":4.47,"timestamp":1784275691004,"preClose":4.83,"halted":0,"volume":13872000,"delay":0,"changeRate":-0.0745341614906833,"floatShares":1804000000,"shares":1804000000,"eps":0.148918,"marketStatus":"Closed","change":-0.36,"latestTime":"07-17 16:08:11","open":4.84,"high":4.84,"low":4.35,"amount":62274580,"amplitude":0.101449,"askPrice":4.47,"askSize":92000,"bidPrice":4.36,"bidSize":21000,"shortable":3,"etf":0,"ttmEps":0.165717,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1784511000000},"marketStatusCode":5,"adr":0,"listingDate":1645545600000,"exchange":"SEHK","adjPreClose":4.83,"openAndCloseTimeList":[[1784251800000,1784260800000],[1784264400000,1784275200000]],"volumeRatio":1.002064,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02157","defaultTab":"news","newsList":[{"id":"1198638968","title":"LEPU BIOPHARMA Names Ren Fangyuan Employee Representative Supervisor After Zhao Lixuan Resignation","url":"https://stock-news.laohu8.com/highlight/detail?id=1198638968","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1198638968?lang=en_us&edition=fundamental","pubTime":"2026-07-15 17:45","pubTimestamp":1784108728,"startTime":"0","endTime":"0","summary":"LEPU BIOPHARMA CO., LTD. announced that employee representative supervisor Zhao Lixuan resigned effective 15 July 2026 to pursue other professional engagements. Zhao confirmed no disagreements with...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166197418","title":"LEPU BIO Announces New Employee Representative Supervisor Appointment","url":"https://stock-news.laohu8.com/highlight/detail?id=1166197418","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166197418?lang=en_us&edition=fundamental","pubTime":"2026-07-15 16:58","pubTimestamp":1784105904,"startTime":"0","endTime":"0","summary":"An announcement has been issued by LEPU BIO (02157).The company's board of supervisors received a written resignation letter from its employee representative supervisor, Ms. Zhao Lixuan, on July 15,...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651455955","title":"Lepu Biopharma Names Ren Fangyuan Employee Representative Supervisor, Replacing Zhao Lixuan","url":"https://stock-news.laohu8.com/highlight/detail?id=2651455955","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651455955?lang=en_us&edition=fundamental","pubTime":"2026-07-15 16:49","pubTimestamp":1784105370,"startTime":"0","endTime":"0","summary":"Lepu Biopharma names Ren Fangyuan employee representative supervisor, replacing Zhao LixuanLepu Biopharma replaced employee representative supervisor Zhao Lixuan, effective July 15, 2026.Ren Fangyuan ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260715:nNDL1bLRQG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193879863","title":"LEPU BIO Shares Surge Again, Gaining Over 7% on Promising Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=1193879863","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193879863?lang=en_us&edition=fundamental","pubTime":"2026-07-15 10:30","pubTimestamp":1784082623,"startTime":"0","endTime":"0","summary":"Shares of LEPU BIO (02157) have surged more than 7%, extending a monthly gain of nearly 30%. At the time of writing, the stock is up 6.01% to HK$4.94, with a turnover of HK$32.62 million. The...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCAI","02157","BK1161","VXUS","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649633957","title":"Lepu Biopharma (SEHK:2157) Rebound Puts Its Valuation Back In Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2649633957","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649633957?lang=en_us&edition=fundamental","pubTime":"2026-07-08 09:32","pubTimestamp":1783474335,"startTime":"0","endTime":"0","summary":"Lepu Biopharma (SEHK:2157) stock has been moving without a clear headline catalyst, leaving investors to focus on its recent price swings, revenue profile and ongoing oncology drug portfolio when assessing the shares.\nSee our latest analysis for Lepu Biopharma.\nThe latest move leaves Lepu Biopharma trading at HK$4.3, after a 1 week share price return of about 11% and a 1 month gain of roughly 12%. However, the weaker 3 month and 1 year total shareholder returns indicate that momentum has been...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/lepu-biopharma-sehk2157-rebound-puts-its-valuation-back-in-f","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/lepu-biopharma-sehk2157-rebound-puts-its-valuation-back-in-f","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1170700150","title":"LEPU BIO Posts Static Share Capital in June 2026, Confirms Sufficient Public Float","url":"https://stock-news.laohu8.com/highlight/detail?id=1170700150","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1170700150?lang=en_us&edition=fundamental","pubTime":"2026-07-06 18:29","pubTimestamp":1783333786,"startTime":"0","endTime":"0","summary":"Lepu Biopharma Co., Ltd. (LEPU BIO) filed its Monthly Return to Hong Kong Exchanges for the period ended 30 June 2026, showing no movement in either authorised or issued share capital. The authorised...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1149233574","title":"Hong Kong Innovative Drug Stocks Jump With HAIXI PHARMA and INNOCARE up 7%; KEYMED up 5%, REMEGEN up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1149233574","media":"Tiger Newspress","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1149233574?lang=en_us&edition=fundamental","pubTime":"2026-07-06 09:58","pubTimestamp":1783303082,"startTime":"0","endTime":"0","summary":"Hong Kong innovative drug stocks jumped in market trading. $HAIXI PHARMA(02637)$, $INNOCARE(09969)$ up 7%; $KEYMED BIO-B(02162)$ up 5%; $REMEGEN(09995)$, $INNOVENT BIO(01801)$, $SIMCERE PHARMA(02096)$ up 4%; $LEPU BIO(02157)$ up 3%.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"330240692f324d079ccf839d9e4180bf","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157","09969","09995","02096","01801","02162","SOXL","02637"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1171576620","title":"LEPU BIO Shares Surge Over 13% in Morning Session as Analyst Highlights Potential of MRG006A in Liver Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1171576620","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1171576620?lang=en_us&edition=fundamental","pubTime":"2026-06-29 11:22","pubTimestamp":1782703341,"startTime":"0","endTime":"0","summary":"Shares of LEPU BIO (HKEX: 02157) experienced a significant surge of over 13% in morning trading. By the time of writing, the stock had risen 12.57% to HK$4.03, with a trading volume of HK$36.31...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","02157","VXUS","BK4585","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1155213622","title":"LEPU BIO Shares Surge Over 6% in Afternoon Trading on Promising Liver Cancer Drug Data","url":"https://stock-news.laohu8.com/highlight/detail?id=1155213622","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1155213622?lang=en_us&edition=fundamental","pubTime":"2026-06-12 14:58","pubTimestamp":1781247504,"startTime":"0","endTime":"0","summary":"Shares of LEPU BIO (HKEX: 02157) rose more than 6% in afternoon trading. At the time of writing, the stock was up 4.74% to HK$3.98, with a turnover of HK$41.495 million.The upward movement follows...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","02157","BK1161","VXUS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187497096","title":"LEPU BIO-B Maintains 1.80 Billion Issued Shares in May 2026; Public Float Remains Compliant","url":"https://stock-news.laohu8.com/highlight/detail?id=1187497096","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187497096?lang=en_us&edition=fundamental","pubTime":"2026-06-01 18:06","pubTimestamp":1780308370,"startTime":"0","endTime":"0","summary":"Lepu Biopharma Co., Ltd. (LEPU BIO-B) reported no changes to its share capital structure for the month ended 31 May 2026, according to the company’s monthly return filed with Hong Kong Exchanges and...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145734625","title":"Lepu Biopharma Updates Articles of Association; Registered Capital Set at RMB 1.80 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1145734625","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145734625?lang=en_us&edition=fundamental","pubTime":"2026-05-19 20:05","pubTimestamp":1779192302,"startTime":"0","endTime":"0","summary":"Lepu Biopharma Co., Ltd. (LEPU BIO-B, 02157) released a revised Articles of Association dated May 2026, detailing its capital structure, governance framework and financial policies. Key points are as...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169927500","title":"LEPU Biopharma Shareholders Endorse All 2025 AGM Items, Confirm New Supervisor and Shanghai Registered Address","url":"https://stock-news.laohu8.com/highlight/detail?id=1169927500","media":"Bulletin Express","labels":["executive","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169927500?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:43","pubTimestamp":1779191007,"startTime":"0","endTime":"0","summary":"LEPU Biopharma Co., Ltd. (LEPU BIO-B, 02157) announced that all nine ordinary and two special resolutions tabled at the 2025 Annual General Meeting on 19 May 2026 were approved by poll. • Voting...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1109034397","title":"LEPU BIO-B (02157) Appoints Fan Xinyu as Supervisory Board Member","url":"https://stock-news.laohu8.com/highlight/detail?id=1109034397","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1109034397?lang=en_us&edition=fundamental","pubTime":"2026-05-19 19:40","pubTimestamp":1779190816,"startTime":"0","endTime":"0","summary":"LEPU BIO-B (02157) announced that Ms. Fan Xinyu has been elected as a member of the second-term Supervisory Board, effective from May 19, 2026.","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630132518","title":"TOT BIOPHARM publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2630132518","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630132518?lang=en_us&edition=fundamental","pubTime":"2026-04-28 12:08","pubTimestamp":1777349286,"startTime":"0","endTime":"0","summary":"BioDlink annual report for FY 2025 outlined continued shift toward integrated biologics CDMO, with ADC programs driving pipeline expansion.CDMO revenue rose 13% to RMB 234.94 million, offsetting weaker self-developed product sales as domestic competition intensified.Project count increased to 213, with ADC-related work representing 68% of projects.BioDlink supported Lepu Biopharma MEIYOUHENG marketing clearance in China on Oct. 30, 2025, positioning platform for commercial ADC manufacturing orders.WuXi XDC proposed acquisition at HKD 4 per share, with transaction expected to complete in first half of 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. TOT BIOPHARM International Co. Ltd. published the original content used to generate ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260428:nNDL5hgbzK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157","BK1161","BK1574","01875"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187482142","title":"Lepu Bio-B Proposes Appointment of Fan Xinyu as Supervisor","url":"https://stock-news.laohu8.com/highlight/detail?id=1187482142","media":"Stock News","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187482142?lang=en_us&edition=fundamental","pubTime":"2026-04-27 21:50","pubTimestamp":1777297837,"startTime":"0","endTime":"0","summary":"Lepu Bio-B (02157) announced that the board of directors has proposed the appointment of Ms. Fan Xinyu as a supervisor. If approved by shareholders at the annual general meeting, her term will...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1162729426","title":"LEPU BIO-B Releases 2025 Board Package, Maintains Zero Dividend and Seeks 20% Share Issuance Mandate","url":"https://stock-news.laohu8.com/highlight/detail?id=1162729426","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1162729426?lang=en_us&edition=fundamental","pubTime":"2026-04-27 21:23","pubTimestamp":1777296183,"startTime":"0","endTime":"0","summary":"LEPU BIO-B (Lepu Biopharma Co., Ltd.) has distributed its 2025 annual general-meeting (AGM) circular, setting out key proposals for shareholder approval on 19 May 2026 in Beijing. Key AGM Items   1....","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630394772","title":"Lepu Biopharma announces annual shareholder meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2630394772","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630394772?lang=en_us&edition=fundamental","pubTime":"2026-04-27 21:15","pubTimestamp":1777295735,"startTime":"0","endTime":"0","summary":"Lepu Biopharma will hold its 2025 annual general meeting in Beijing on May 19, 2026.Shareholders will vote on 2025 reports and accounts, including board and supervisors’ reports, annual report, and financial statements.Items include 2026 budget, 2025 profit distribution plan, reappointment of Ernst & Young as auditor for 2026.Other proposals cover appointment of a supervisor, change of registered address, amendments to articles of association.Meeting will also consider a general mandate for the board to issue, allot, and deal with additional shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Lepu Biopharma Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260427:nNDL4QJc6p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135394572","title":"乐普生物2025年营收显著增长并成功扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=1135394572","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135394572?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:26","pubTimestamp":1776860775,"startTime":"0","endTime":"0","summary":"乐普生物于2025财年实现营业收入约人民币9.35亿元（2024年为人民币3.68亿元），同比大幅增长，主要来自核心在研和已上市肿瘤治疗产品的商业化，以及技术平台对外授权收入。公司当期净利润约人民币2.59亿元，相较2024年净亏损人民币4.24亿元显著好转，其中归属于公司股东的净利润约人民币2.61亿元，这是公司上市以来首次在年度层面实现盈利。...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"乐普生物2025年营收显著增长并成功扭亏为盈","news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629464650","title":"Lepu Biopharma publishes 2025 annual report","url":"https://stock-news.laohu8.com/highlight/detail?id=2629464650","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629464650?lang=en_us&edition=fundamental","pubTime":"2026-04-22 20:18","pubTimestamp":1776860286,"startTime":"0","endTime":"0","summary":"Lepu Biopharma published 2025 annual report, highlighting first full-year profit on stronger product sales and licensing income.MEIYOUHENG, EGFR-targeted ADC, secured NMPA marketing clearance in October 2025 for relapsed or metastatic nasopharyngeal cancer, supporting China launch.Pipeline advanced toward late-stage readouts, with Phase III programs running for MEIYOUHENG in head and neck cancer, MRG004A in pancreatic cancer, and confirmatory Phase III studies for PD-1 antibody PUYOUHENG.Business development expanded, led by out-licensing MRG007 ex-Greater China to ArriVent with deal value up to USD 1.2 billion, including upfront, milestones, and tiered royalties.Manufacturing footprint scaled, with Beijing facility supporting clinical supply and CDMO work, while Shanghai Biotech Park built out for mAb and ADC production.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260422:nNDL20zyTB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02157","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625935640","title":"Assessing Lepu Biopharma’s Valuation After Earnings Turnaround And Share Price Surge","url":"https://stock-news.laohu8.com/highlight/detail?id=2625935640","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625935640?lang=en_us&edition=fundamental","pubTime":"2026-04-06 01:16","pubTimestamp":1775409405,"startTime":"0","endTime":"0","summary":"Earnings turnaround puts Lepu Biopharma back on investors’ radar\nLepu Biopharma (SEHK:2157) has drawn fresh attention after reporting full year 2025 results that shifted from a net loss to net income of CNY 261.36 million, with sales of CNY 934.87 million.\nThe company also moved from a basic loss per share of CNY 0.24 to basic earnings per share of CNY 0.15 from continuing operations, a change that gives investors new financial data points to assess the stock.\nSee our latest analysis for Lepu...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/assessing-lepu-biopharmas-valuation-after-earnings-turnaroun","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-2157/lepu-biopharma-shares/news/assessing-lepu-biopharmas-valuation-after-earnings-turnaroun","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["02157","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.lepubiopharma.com","stockEarnings":[{"period":"1week","weight":0.1555},{"period":"1month","weight":0.2812},{"period":"3month","weight":-0.2418},{"period":"6month","weight":-0.1282},{"period":"1year","weight":-0.0548},{"period":"ytd","weight":-0.0282}],"compareEarnings":[{"period":"1week","weight":0.0407},{"period":"1month","weight":0.021},{"period":"3month","weight":-0.044},{"period":"6month","weight":-0.0684},{"period":"1year","weight":0.02},{"period":"ytd","weight":-0.0243}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Lepu Biopharma Co Ltd is a company principally engaged in the sales of pharmaceutical products and the research and development of new drugs. The Company is focused on oncology therapeutics, in particular, targeted therapy and oncology immunotherapy. The Company is dedicated to developing innovative antibody-drug conjugate (ADC) through an ADC technology development platform. The Company’s clinical-stage drug candidates cover targeted therapeutics and an immunotherapeutic, including MRG003, MRG002, CMG901, MRG004A, CG0070, MRG006A, MRG007, and CTM012.","yearOnYearQuotes":[{"month":1,"riseRate":0.25,"avgChangeRate":-0.070458},{"month":2,"riseRate":0.5,"avgChangeRate":0.087235},{"month":3,"riseRate":0.4,"avgChangeRate":-0.009016},{"month":4,"riseRate":0.8,"avgChangeRate":0.177486},{"month":5,"riseRate":0.4,"avgChangeRate":-0.041488},{"month":6,"riseRate":0.4,"avgChangeRate":-0.053819},{"month":7,"riseRate":0.6,"avgChangeRate":0.102327},{"month":8,"riseRate":0.5,"avgChangeRate":-0.002458},{"month":9,"riseRate":0.5,"avgChangeRate":0.085192},{"month":10,"riseRate":0.25,"avgChangeRate":-0.14162},{"month":11,"riseRate":0.25,"avgChangeRate":0.007333},{"month":12,"riseRate":0.25,"avgChangeRate":-0.05091}],"exchange":"SEHK","name":"LEPU BIO","nameEN":"LEPU BIO"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"LEPU BIO(02157),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest LEPU BIO(02157) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"LEPU BIO,02157,LEPU BIO股票,LEPU BIO股票老虎,LEPU BIO股票老虎国际,LEPU BIO行情,LEPU BIO股票行情,LEPU BIO股价,LEPU BIO股市,LEPU BIO股票价格,LEPU BIO股票交易,LEPU BIO股票购买,LEPU BIO股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"LEPU BIO(02157),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest LEPU BIO(02157) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}